3,322
Views
5
CrossRef citations to date
0
Altmetric
Vaccines

Incremental net monetary benefit of herpes zoster vaccination: a systematic review and meta-analysis of cost-effectiveness evidence

ORCID Icon, , ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 26-37 | Received 09 Sep 2021, Accepted 16 Nov 2021, Published online: 08 Dec 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Sajesh K. Veettil, Vanessa Vincent, Taylor Shufelt, Emma Behan, M. Sakil Syeed, Ammarin Thakkinstian, David C. Young & Nathorn Chaiyakunapruk. (2023) Incremental net monetary benefit of biologic therapies in moderate to severe asthma: a systematic review and meta-analysis of economic evaluation studies. Journal of Asthma 60:9, pages 1702-1714.
Read now
Nikolaos Giannelos, Cheryl Ng & Desmond Curran. (2023) Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review. Human Vaccines & Immunotherapeutics 19:1.
Read now
Ru Han, Jorge A. Gomez, Bruna de Veras, Thatiana Pinto, Adriana Guzman-Holst, Javier Nieto & Désirée A. M. van Oorschot. (2023) How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?. Human Vaccines & Immunotherapeutics 19:1.
Read now

Articles from other publishers (2)

Mischa Pier, Gertjan Wolbink & Laura Boekel. (2024) Time to talk to adults with rheumatic diseases about herpes zoster vaccination. The Lancet Rheumatology.
Crossref
Fiona Ecarnot & Jean-Pierre Michel. (2022) The untapped potential of herpes zoster vaccination. The Lancet Healthy Longevity 3:4, pages e223-e224.
Crossref